Platinum Resistant Ovarian Cancer clinical trials

Explore recruiting platinum resistant ovarian cancer clinical trials.

Recruiting platinum resistant ovarian cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Platinum Resistant Ovarian Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer

Spain, Norway, Czechia, Netherlands, Germany, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

Italy, Norway, Spain, France, Denmark, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

Spain, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

Ireland, Poland, France, Netherlands, Spain, Italy +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination with Niraparib and ZN-c3 Monotherapy in Subjects with Platinum-resistant Ovarian Cancer.

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Platinum Resistant Ovarian Cancer trials by city

Platinum Resistant Ovarian Cancer in Toronto Platinum Resistant Ovarian Cancer in Vancouver Platinum Resistant Ovarian Cancer in Montreal Platinum Resistant Ovarian Cancer in Calgary Platinum Resistant Ovarian Cancer in Edmonton Platinum Resistant Ovarian Cancer in Ottawa Platinum Resistant Ovarian Cancer in Winnipeg Platinum Resistant Ovarian Cancer in Quebec City Platinum Resistant Ovarian Cancer in Hamilton Platinum Resistant Ovarian Cancer in Kitchener Platinum Resistant Ovarian Cancer in London Platinum Resistant Ovarian Cancer in Halifax Platinum Resistant Ovarian Cancer in New York Platinum Resistant Ovarian Cancer in Los Angeles Platinum Resistant Ovarian Cancer in Chicago Platinum Resistant Ovarian Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease